TY - JOUR
T1 - Immune and Angiogenic Profiling of Mesenchymal Stem Cell Functions in a Subcutaneous Microenvironment for Allogeneic Islet Transplantation
AU - Campa-Carranza, Jocelyn Nikita
AU - Capuani, Simone
AU - Joubert, Ashley L.
AU - Hernandez, Nathanael
AU - Bo, Tommaso
AU - Sauceda-Villanueva, Octavio I.
AU - Conte, Marzia
AU - Franco, Letizia
AU - Farina, Marco
AU - Rome, Gabrielle E.
AU - Xu, Yitian
AU - Zheng, Junjun
AU - Argueta, Lissenya B.
AU - Niles, Jean A.
AU - Nikolos, Fotis
AU - Chua, Corrine Ying Xuan
AU - Chen, Shu Hsia
AU - Nichols, Joan E.
AU - Kenyon, Norma S.
AU - Grattoni, Alessandro
N1 - Publisher Copyright:
© 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH.
PY - 2025/5/29
Y1 - 2025/5/29
N2 - Islet transplantation offers a promising treatment for type 1 diabetes (T1D), by aiming to restore insulin production and improve glycemic control. However, T1D is compounded by impaired angiogenesis and immune dysregulation, which hinder the therapeutic potential of cell replacement strategies. To address this, this work evaluates the proangiogenic and immunomodulatory properties of mesenchymal stem cells (MSCs) to enhance vascularization and modulate early-stage immune rejection pathways in the context of islet allotransplantation. This work employs the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) platform, a subcutaneous vascularized implant with localized immunomodulation developed by the group. This study assesses vascularization and immune regulation provided by MSCs, aiming to improve islet survival and integration in diabetic rats while considering sex as a biological variable. These findings demonstrate that MSCs significantly enhance vascularization and modulate the local microenvironment during the peri-transplant period. Importantly, this work discovers sex-specific differences in both processes, which influence islet engraftment and long-term function.
AB - Islet transplantation offers a promising treatment for type 1 diabetes (T1D), by aiming to restore insulin production and improve glycemic control. However, T1D is compounded by impaired angiogenesis and immune dysregulation, which hinder the therapeutic potential of cell replacement strategies. To address this, this work evaluates the proangiogenic and immunomodulatory properties of mesenchymal stem cells (MSCs) to enhance vascularization and modulate early-stage immune rejection pathways in the context of islet allotransplantation. This work employs the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) platform, a subcutaneous vascularized implant with localized immunomodulation developed by the group. This study assesses vascularization and immune regulation provided by MSCs, aiming to improve islet survival and integration in diabetic rats while considering sex as a biological variable. These findings demonstrate that MSCs significantly enhance vascularization and modulate the local microenvironment during the peri-transplant period. Importantly, this work discovers sex-specific differences in both processes, which influence islet engraftment and long-term function.
KW - Type 1 diabetes
KW - immunomodulation
KW - islet engraftment
KW - mesenchymal stem cells
KW - sex-specific differences
KW - vascularized subcutaneous microenvironment
UR - http://www.scopus.com/inward/record.url?scp=105004704676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105004704676&partnerID=8YFLogxK
U2 - 10.1002/advs.202411574
DO - 10.1002/advs.202411574
M3 - Article
C2 - 40344470
AN - SCOPUS:105004704676
SN - 2198-3844
VL - 12
JO - Advanced Science
JF - Advanced Science
IS - 20
M1 - 2411574
ER -